First Participant Dosed in Phase 1a Study of Oral HDV Entry Inhibitor
Assembly Biosciences has dosed the first participant in a Phase 1a clinical trial for ABI-6250, an oral HDV entry...
PDS Biotech’s HPV Cancer Data in JAMA Oncology: Positive Survival, Clinical Responses
PDS Biotechnology Corporation announced promising clinical trial results for a triple combination therapy targeting HPV-associated cancers, published in JAMA...
Pyx-201 Gets FDA Fast Track for Head & Neck Cancer
Pyxis Oncology’s PYX-201, an antibody-drug conjugate targeting Extradomain-B Fibronectin (EDB+FN), received Fast Track Designation from the FDA for treating...
Lucid-21-302 Phase 1 Trial Complete: Quantum Biopharma’s MS Drug Shows Promise
Quantum BioPharma Ltd. announced the successful completion of a Phase 1 clinical trial for Lucid-MS, a novel neuroprotective compound...
Plus Therapeutics Rhenium-186 Obisbemeda: A Promising Therapeutic for Leptomeningeal Metastases
Plus Therapeutics completed its Phase 1 single-dose escalation trial of Rhenium (¹⁸⁶Re) Obisbemeda, administered intrathecally, for patients with leptomeningeal...
FDA Accepts Regeneron Odronextamab Resubmission for Follicular Lymphoma Review
Regeneron Pharmaceuticals announced that the FDA accepted its resubmitted Biologics License Application (BLA) for odronextamab. The drug is intended...
How AI is Minimizing Clinical Trial Protocol Amendments
In this interview, we sit down with Catherine (Cat) Hall, Head of GXP Quality at Egnyte, to discuss how...
Emalex Biosciences Tourette Syndrome Study Meets Endpoints
Emalex Biosciences’ Phase 3 trial of ecopipam, a dopamine-1 receptor antagonist, demonstrated statistically significant improvement in Tourette syndrome symptoms...
TNF Pharmaceuticals Launches Phase 2b Trial of Oral TNF Inhibitor
TNF Pharmaceuticals has initiated a fully funded Phase 2b clinical trial for isomyosamine, an oral TNF-α inhibitor, targeting muscle...
Coya Therapeutics in BTIG KOL Call on Alzheimer’s & GLP-1
Coya Therapeutics is advancing COYA 303, a combination therapy of low-dose interleukin-2 (COYA 301) and a GLP-1 receptor agonist,...